Egypt-based Holding Company for Biological Products and Vaccines (VACSERA) is negotiating with China’s Sinovac Biotech Ltd over the establishment of an integrated plant for the production of vaccines, Al-Borsa News reported on January 4th.

According to VACSERA’s 2022 business wrap-up report, the company produced around 50 million doses of the Covid-19 vaccine VACSERA-SINOVAC.

In June 2022, VACSERA settled debts of EGP 712.5 million for National Investment Bank, the report showed.

Within the framework of the localization of the vaccines industry’s strategy in Egypt, the company signed several agreements to pass down the knowledge of the necessary manufacturing technologies that would meet the demands of the health ministry for vaccines, the report added.